Clinical Trials Browser

Interventional × Neoplasms × carfilzomib × Clear all

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT04263480 2025-04-04

CZAR-1

Phase 2 Active not recruiting

Waldenstrom Macroglobulinemia, Neoplasms

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT04895410 2023-03-06

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

Phase 1 Terminated

Multiple Myeloma, Neoplasms, Recurrence

NCT02257476 2017-02-07

Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT02235740 2016-05-04

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Phase 1 Terminated

Multiple Myeloma, Neoplasms, Recurrence